吉西他滨联合奥沙利铂治疗复发和难治性弥漫性大B细胞淋巴瘤的疗效观察  

Gemcitabine combined with oxaliplatin in treatment of relapsed and refractory diffuse large B-cell lymphoma

作　　者：刘永钟[1] 梁淑仪[2] 林贵南[1] 彭杰文[1] 殷兆锋[1] 梁汉霖[1] 贺景焕[1] 

机构地区：[1]广东省中山市人民医院化疗科,528403 [2]广东省中山市人民医院脑科,528403

出　　处：《中国医药》2012年第11期1391-1393,共3页China Medicine

摘　　要：目的探讨GEMOX方案（吉西他滨联合奥沙利铂）治疗复发和难治性弥漫性大B细胞淋巴瘤（DLBCL）的近期疗效和不良反应。方法27例复发和难治性DLBCL采用GEMOX方案治疗：吉西他滨（GEM）1000mg／m2静脉滴注，第1、8天；奥沙利铂（L—OHP）100mg／m2静脉滴注，第2天。2组均21d为1个周期，疗程不少于2个周期。观察疗效和不良反应，并随访疾病进展情况。结果27例均能评价疗效（其中复发17例，难治10例），复发者总缓解率为64．7％（11／17），中位肿瘤进展时间（TTP）为7．5个月（95％C16．8～8．2个月）；难治者总缓解率为60．0％（6／10），中位肿瘤进展时间为6．2个月（95％CI5．3—7．1个月）。复发和难治患者总缓解率比较差异无统计学意义（P〉0．05），但中位肿瘤进展时间差异有统计学意义（P〈0．05）；化疗不良反应程度较轻，主要不良反应为白细胞和血小板减少，但均为可逆，未出现因化疗毒性而死亡病例。结论GEMOX方案是治疗复发和难治性DLBCL安全有效的可行性解救方案。Objective To evaluate the short-term effect and side effects of GEMOX regimen in treating the patients with relapsed and refractory diffuse large B-cell lymphoma （DLBCL）. Methods Twenty-seven patients with relapsed and refractory DLBCL were treated with GEMOX regimen, GEMOX regimen： gemcitabine （GEM） 1000 mg/m2 IVD on day 1 and 8 ; oxaliplatin （L-OHP） 100 mg/m2 IVD on day 2 ; treatment was repeated every 3 weeks with at least 2 cycles of chemotherapy for each patient. Results The response rate of relapsed group was 64. 7% （11/17） ; the median time to progression （m-TIP） was 7.5 months （95% CI 6.8-8.2 months）. The response rate of refractory group was 60.0% （6/10） and m-TYP was 6.2 months（95% CI 5.3-7.1 months）. There were no differences between relapsed group and refractory group in the response rate, but there were differences in m-TIP. The main side effects included marrow suppression such as leucopenia and thrombocytopenia. No patients died of toxic reactions of chemotherapy. Conclusion GEMOX regimen is a safe and effective salvage regimen for the patients with relapsed and refractory DLBCL.

关 键 词：弥漫性大B细胞淋巴瘤 化学疗法 吉西他滨 奥沙利铂 

分 类 号：R733[医药卫生—肿瘤]